DK1205559T3 - Fremgangsmåde til påvisning af patogene mikroorganismer og antimikrobielle midler, fremgangsmåde til vurdering af lægemiddelvirkningen af antimikrobielle midler, og antimikrobielle midler - Google Patents

Fremgangsmåde til påvisning af patogene mikroorganismer og antimikrobielle midler, fremgangsmåde til vurdering af lægemiddelvirkningen af antimikrobielle midler, og antimikrobielle midler

Info

Publication number
DK1205559T3
DK1205559T3 DK00944390T DK00944390T DK1205559T3 DK 1205559 T3 DK1205559 T3 DK 1205559T3 DK 00944390 T DK00944390 T DK 00944390T DK 00944390 T DK00944390 T DK 00944390T DK 1205559 T3 DK1205559 T3 DK 1205559T3
Authority
DK
Denmark
Prior art keywords
antimicrobials
evaluating
drug effect
pathogenic microorganisms
detecting pathogenic
Prior art date
Application number
DK00944390T
Other languages
Danish (da)
English (en)
Inventor
Yoshiyuki Tatsumi
Mamoru Yokoo
Kosho Nakamura
Tadashi Arika
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16654658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1205559(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of DK1205559T3 publication Critical patent/DK1205559T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
DK00944390T 1999-07-28 2000-07-11 Fremgangsmåde til påvisning af patogene mikroorganismer og antimikrobielle midler, fremgangsmåde til vurdering af lægemiddelvirkningen af antimikrobielle midler, og antimikrobielle midler DK1205559T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21436999 1999-07-28
PCT/JP2000/004617 WO2001007643A1 (fr) 1999-07-28 2000-07-11 Methode de detection d'un micro-organisme pathogene et d'un agent antimicrobien, methode d'evaluation des effets medicamenteux de l'agent antimicrobien, et agent antimicrobien

Publications (1)

Publication Number Publication Date
DK1205559T3 true DK1205559T3 (da) 2009-09-28

Family

ID=16654658

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944390T DK1205559T3 (da) 1999-07-28 2000-07-11 Fremgangsmåde til påvisning af patogene mikroorganismer og antimikrobielle midler, fremgangsmåde til vurdering af lægemiddelvirkningen af antimikrobielle midler, og antimikrobielle midler

Country Status (12)

Country Link
US (2) US7214506B2 (fr)
EP (2) EP2112228A1 (fr)
JP (2) JP4414623B2 (fr)
AT (1) ATE434667T1 (fr)
AU (1) AU5852400A (fr)
CA (1) CA2391274C (fr)
CY (1) CY1109281T1 (fr)
DE (1) DE60042453D1 (fr)
DK (1) DK1205559T3 (fr)
ES (1) ES2328785T3 (fr)
PT (1) PT1205559E (fr)
WO (1) WO2001007643A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013862A1 (en) * 2004-07-19 2006-01-19 Held Jerry M Onychomycosis: a new process for cure
JP4824493B2 (ja) * 2005-08-31 2011-11-30 株式会社ポーラファルマ 抗真菌剤の評価法
CA2673976C (fr) 2006-12-28 2015-02-17 Kaken Pharmaceutical Co., Ltd. Composition de gel pour traiter une mycose
WO2009081976A1 (fr) * 2007-12-25 2009-07-02 Pola Pharma Inc. Modèle d'infection animale pour infection microbienne
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US12544491B2 (en) 2009-08-24 2026-02-10 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US20130196318A1 (en) * 2010-04-16 2013-08-01 Shawn Mark O'Hara Methods for measuring enzyme activity useful in determining cell viability in non-purified samples
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
CA2974180A1 (fr) * 2015-01-20 2016-07-28 Itai Adin Formes cristallines d'efinaconazole
KR102060546B1 (ko) 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
JP7440073B2 (ja) * 2020-07-30 2024-02-28 国立大学法人広島大学 生存細菌の検出方法及びそのためのキット
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물
KR102863832B1 (ko) 2021-05-04 2025-09-25 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233502A (en) * 1989-06-09 1991-11-26 Janssen Pharmaceutica Nv 4-(1,2,4-triazole- or imidazole-phenyl-substituted) -1-(1,3-dioxolan-4-ylmethoxyphenyl) piperazine derivatives; preparatory processes: fungicidal and antiviral compositions
UA41365C2 (uk) * 1993-05-10 2001-09-17 Какєн Фармасьютікал Ко., Лтд Похідні азоліламіну та фунгіцидний засіб на їх основі
JPH09504176A (ja) * 1993-10-25 1997-04-28 ライボジーン、インコーポレイテッド 抗真菌剤の選抜法
JP3404152B2 (ja) * 1994-10-04 2003-05-06 ポーラ化成工業株式会社 抗真菌剤の評価法
JP3129662B2 (ja) * 1996-07-16 2001-01-31 グンゼ株式会社 皮膚刺激判定法
CA2278328C (fr) * 1998-02-09 2008-07-22 Macrochem Corporation Vernis a ongles antifongique et son procede d'utilisation

Also Published As

Publication number Publication date
CA2391274A1 (fr) 2001-02-01
ATE434667T1 (de) 2009-07-15
US7214506B2 (en) 2007-05-08
US20080003636A1 (en) 2008-01-03
AU5852400A (en) 2001-02-13
EP1205559A4 (fr) 2004-11-17
US20070082375A1 (en) 2007-04-12
EP2112228A1 (fr) 2009-10-28
ES2328785T3 (es) 2009-11-18
CY1109281T1 (el) 2014-07-02
CA2391274C (fr) 2010-12-14
EP1205559A1 (fr) 2002-05-15
PT1205559E (pt) 2009-08-04
JP2010004893A (ja) 2010-01-14
EP1205559B1 (fr) 2009-06-24
JP4414623B2 (ja) 2010-02-10
DE60042453D1 (de) 2009-08-06
WO2001007643A1 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
DK1205559T3 (da) Fremgangsmåde til påvisning af patogene mikroorganismer og antimikrobielle midler, fremgangsmåde til vurdering af lægemiddelvirkningen af antimikrobielle midler, og antimikrobielle midler
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
WO2004027020A3 (fr) Identification d'une enzyme lytique associee a un phage visant a detecter et a eliminer rapidement et specifiquement bacillus anthracis
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
NO20025204L (no) Forbindelser og fremgangsmåter for behandling og forebygging av bakteriellinfeksjon
BR0200294B1 (pt) sistema e mÉtodo de processamento de algodço.
DK1183269T3 (da) Svækkede mikroorganismer til behandlingen af infektion
EA200001197A1 (ru) Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина
EP1706128A4 (fr) Compositions pharmaceutiques et methodes de traitement a l'insuline
DK1504088T3 (da) Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner
WO2000056333A8 (fr) Combinaison d'antibiotique et de compose de fixation d'acides nucleiques, destinee a surmonter la resistance de bacteries aux antibiotiques
DK2022786T3 (da) Middel mod mund- og klovsyge-virus til dyr, der hører til familien suidae eller får, og fremgangsmåde til forebyggelse eller behandling af mund- og klovsyge hos dyr, der hører til familien suidae eller får
WO2007053176A3 (fr) Methode de protection contre une infection a staphylocoque
ATE372132T1 (de) Verfahren zum sterilisieren von gegenständen
NO20065671L (no) Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier.
ATE404215T1 (de) Pharmazeutische zusammensetzung zur behandlung einer hiv-infektion
CY1105309T1 (el) Συμπλεγμα εμβολιου που προοριζεται για προληψη και θepαπεια των λεϊσμανιασεων
DE50303478D1 (de) Testsystem zur evaluierung der kompatibilität biologisch aktiver substanzen mit copolymeren
FR2814066B1 (fr) Procede de deformation permanente des matieres keratiniques mettant en oeuvre un agent absorbant organique
DK1184398T3 (da) Oligomer til medier til indfangning af mikroorganismer, oligomerpolymeriseret vandholdig gel og oligomerpolymeriseret mikroorganismeindfangende gel
DE60140611D1 (de) Verfahren zum evaluieren antifungaler agensien
WO2002002087A3 (fr) Produits anthelminthiques permettant de prevenir les infections parasitaires chez l'homme et l'animal ii
RU97113193A (ru) Штамм бактерий bacillus anthracis 81/1, используемый в качестве тест-заражающей культуры
TH95334A (th) การใช้ของวัคซีนสำหรับการรักษา/การป้องกันของการแพร่เชื้อของจุลชีพก่อโรค
DE602004031127D1 (de) Attenuierte bakterielle lebendvakzine